Find biotech stock picks across drug pipelines, clinical trials, and FDA decisions. Top plays in large pharma and small-cap biotech for investors.
No posts in this category yet.
Biotech is where binary catalysts can deliver 200%+ moves on a single trial readout. It is also where most small-cap names eventually fail. Self-directed investors who play this sector well do their pipeline homework, understand FDA timelines, and size positions for asymmetric outcomes. Roughly 90% of clinical-stage drug candidates fail to reach market approval, making concentrated biotech bets among the highest-risk trades retail can make.
The sector still rewards diligent investors. The top biotech stocks of any given year often deliver 100%+ returns driven by approvals, acquisitions, and successful trial readouts.
Biotech stocks are publicly traded companies developing pharmaceutical drugs, gene therapies, biologics, or related medical technologies based on living systems. The category typically excludes traditional medical device makers and chemistry-based pharmaceuticals (which fall under pharma), though the boundary between biotech and pharma has blurred as large pharma has acquired biotech innovation.
The sector includes large established biotech (Amgen, Gilead, Vertex, Regeneron), mid-cap profitable biotech (Biogen, Moderna, Incyte), clinical-stage biotech with promising trials underway (typically $100M to $5B market cap), and pre-clinical or earlier-stage research companies.
There are five main entry points.
Large pharma with biotech exposure offers the most diversified entry. Eli Lilly (LLY), Johnson and Johnson (JNJ), Pfizer (PFE), Merck (MRK), and AbbVie (ABBV) all run biotech-derived drug pipelines while paying meaningful dividends.
Established profitable biotech combines biotech innovation with mature revenue. Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron (REGN), and Biogen (BIIB) are the largest names.
Mid-cap biotech with key catalysts includes names like Moderna (MRNA), BioMarin (BMRN), Alnylam (ALNY), and Sarepta Therapeutics (SRPT). These have both revenue and meaningful clinical pipeline.
Small-cap clinical-stage biotech offers binary upside. Examples include Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), and Madrigal Pharmaceuticals (MDGL). Position sizing is critical because individual trial failures can wipe out 60%+ of value overnight.
Biotech ETFs include the iShares Nasdaq Biotechnology ETF (IBB), the SPDR S&P Biotech ETF (XBI, equal-weighted, more small-cap exposure), the iShares Genomics, Immunology and Healthcare ETF (IDNA), and the ARK Genomic Revolution ETF (ARKG).
Binary catalysts dominate small-cap biotech. Phase 3 trial outcomes often determine whether a stock 5x's or drops 80%.
FDA timelines drive valuations. PDUFA dates (FDA decision deadlines), advisory committee meetings, and complete response letters all create predictable catalyst windows.
Large pharma acquires biotech innovation. M&A premiums of 50% to 100% over pre-deal prices are common. Speculation around acquisition targets drives some of the largest biotech moves.
Cash runway matters. Pre-revenue biotech companies frequently raise capital through equity offerings, which dilutes existing shareholders. Watching cash on hand and burn rate is essential.
Large Pharma with Biotech Pipelines: LLY, JNJ, PFE, MRK, ABBV, BMY.
Established Profitable Biotech: AMGN, GILD, VRTX, REGN, BIIB.
Mid-Cap Biotech: MRNA, BMRN, ALNY, INCY, SRPT.
Small-Cap Clinical-Stage Biotech: VKTX, CRNX, MDGL, RXRX, BEAM, CRSP.
Therapeutic Areas: oncology (largest segment), rare disease, gene therapy, immunology, neurology.
Biotech ETFs: IBB, XBI, IDNA, ARKG, FBT.
Biotech sector performance moves through extended cycles, with multi-year drawdowns followed by recoveries driven by pharma M&A and successful trial readouts. Major acquirers consistently seek to replace patent-cliff revenue through biotech acquisitions.
The most active therapeutic areas typically include obesity drugs (GLP-1, covered separately), oncology (immunotherapy and targeted therapies), gene therapy (sickle cell, hemophilia, and rare disease), and neurology (including Alzheimer's research, which has produced multiple FDA decisions in recent years).
Patent cliffs are recurring. Large pharma blockbusters face generic competition on a rolling basis, motivating ongoing acquisitions of biotech innovation.
What are the best biotech stocks to buy?
The most-held biotech stocks include Vertex Pharmaceuticals, Amgen, Regeneron, and Gilead Sciences for stability, plus selective clinical-stage names like Viking Therapeutics for binary upside. For diversified exposure, the iShares Nasdaq Biotechnology ETF (IBB) and SPDR S&P Biotech ETF (XBI) bundle large and small-cap biotech respectively.
What is small-cap biotech?
Small-cap biotech generally refers to publicly traded biotech companies with market capitalizations below $2 billion. Most are clinical-stage or pre-revenue, making them higher-risk and higher-reward than large established biotech. The SPDR S&P Biotech ETF (XBI) is equal-weighted, providing more small-cap exposure than the cap-weighted IBB.
What is a PDUFA date?
PDUFA stands for Prescription Drug User Fee Act, which gives the FDA fee-funded resources to review new drug applications under specific deadlines. The PDUFA date is the FDA's targeted decision deadline for a specific drug application. PDUFA decisions can move biotech stocks 30% or more.
What is a Phase 3 trial?
A Phase 3 trial is the largest and most expensive clinical trial typically required before FDA approval. Phase 3 trials test a drug in hundreds to thousands of patients to confirm efficacy and safety. Successful Phase 3 results often lead to FDA approval, while failures typically end a drug program.
What is the best biotech ETF?
The largest biotech-focused ETFs are the iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI). IBB is cap-weighted, dominated by large biotech. XBI is equal-weighted, providing more exposure to small-cap clinical-stage biotech with higher volatility and potential return.
Biotech rewards investors who do their pipeline homework and size positions for binary outcomes. Coverage focuses on US-listed names with material catalysts on the calendar. No "next big thing" hype, no penny-stock pumps, just the trials and approvals that actually move stocks. For specific picks, see our Best Biotech Stocks guide.